Abstract
This month’s snapshot of events in the therapeutic delivery arena covers the period 21 June–21 July 2010 inclusive. Overall it was a highly successful month for companies working in the field, with five products based on nonstandard formulation technologies achieving regulatory approval either in the USA or in the EU. It also saw a number of business negotiations come to fruition, including the announced merger between Biovail and Valeant and the takeover of Abraxis by Celgene. However, the period also witnessed some disappointments, one of the most notable of which is Pfizer’s planned withdrawal of Mylotarg® from the market. The information is sourced from company websites and press releases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
